Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
322
resultados
Última actualización
25/08/2026 [07:57:00]
Resultados 250 a 275 de 322
Resumen de: WO2026147818A1
Isolated monoclonal antibodies that bind to methylated dipeptide repeat proteins (DRPs), e.g., ADMe-GR and SDMe-GR, and related antibody-based compositions and molecules are disclosed. Also disclosed are diagnostic and therapeutic methods for using the antibodies.
Resumen de: US20260196299A1
0000 Methods, systems, and kits are provided for assessing cardiorespiratory fitness and predicting cardiometabolic risk.
Resumen de: WO2026147852A1
In some aspects, the disclosure relates to compositions and method for detection, classification, and treatment of disease or other body status. The methods and compositions may be methods or compositions for identification of diseases in patients using a nanosensor having an enzyme cleavage site linked to a volatile 5 reporter via a dipeptide linker.
Resumen de: WO2026145969A1
Exosome Detection on automated Routine Immunoassay Analyzers The present invention relates to a method for detecting exosomes in a sample comprising providing the exosomes in an aqueous solution; interacting the exosomes with at least one first interactor molecule, wherein the interaction yields a complex comprising both an exosome and the first interactor molecule; interacting the complex of the previous step with at least a second interactor molecule linked to a chemiluminescent dye; interacting the complex of the previous step with a substrate or a bead and thereby immobilizing it; performing a washing step; identifying the complex of the previous step by performing a chemiluminescent reaction, wherein the identification results in a chemiluminescent emission of photons; and detecting the emission of photons. Also envisaged is a corresponding kit for detecting exosomes in a sample.
Resumen de: WO2026146787A1
The purpose of the present invention is to develop a design strategy focusing on central secondary structure motifs, such as α-helix, β-strand, and β-turn, which are important for PPI recognition, by using a common core skeleton, thereby providing a low-molecular-weight PPI modulator having a wide range of therapeutic potentials, and a versatile platform for targeting PPI.
Resumen de: WO2026144428A1
Provided are an scFv antibody that specifically binds Aβ, an isolated nucleic acid encoding the antibody, a vector comprising the nucleic acid, a cell comprising the isolated nucleic acid or the vector, a method for preparing the scFv antibody that specifically binds Aβ, and a use of the scFv antibody that specifically binds Aβ in the preparation of a medicament for treating Alzheimer's disease.
Resumen de: AU2024411321A1
The present disclosure describes methods comprising obtaining a level of a biomarker in a subject and based on the level of the biomarker in the subject, continuing a short chain fatty acid therapy. The disclosed methods can comprise administering a composition comprising at least one short chain fatty acid. The disclosed methods can be used to treat an inflammatory condition, a skin disorder, or an autoimmune disorder.
Resumen de: WO2025046049A1
The present invention relates to molecules that are capable of binding to amyloid fibril aggregates. The invention further describes methods for detecting the presence of amyloid fibril aggregates in a sample or a subject. The invention even further describes methods for treating pathologies caused by amyloid fibril aggregates.
Resumen de: WO2024263558A1
Described are dual transporters and methods of making and using the dual transporters. The dual transporters bind to a blood brain barrier transport protein and a second protein that is expressed on the luminal surface of the blood brain barrier or is a brain retention protein. The dual transporters improve delivery to the central nervous system.
Resumen de: KR20260106387A
본 발명은 퇴행성 뇌질환, 특히 알츠하이머병, 파킨슨병, 헌팅턴병 및 기타 신경퇴행성 질환의 진단 시스템에 관한 것이다. 구체적으로는 다중 바이오마커를 이용하여 퇴행성 뇌질환의 진단을 수행하며, 이를 인공지능 알고리즘을 통해 정확히 분석하여 보다 효과적이고 신속한 진단을 수행할 수 있는 시스템을 제공하는 기술에 관한 것이다.
Resumen de: CN122344252A
本申请公开了一种p‑Tau231特异性抗体及其在阿尔茨海默症辅助诊断试剂盒的应用，属于免疫分析技术领域。本申请抗体重链CDRH1‑CDRH3的氨基酸序列分别依次如SEQ ID NO：1‑SEQ ID NO：3所示，轻链CDRL1的氨基酸序列如SEQ ID NO：4所示，轻链CDRL2的氨基酸序列为QA，轻链CDRL3的氨基酸序列如SEQ ID NO：5所示。本申请还提供了靶向p‑Tau231的抗体、检测p‑Tau231的化学发光试剂盒。本申请抗体亲和力高、灵敏度高且生产周期明显缩短，更适合作为核心原料应用于体外诊断试剂领域，可用于阿尔茨海默症的辅助诊断。
Resumen de: KR20260106296A
본 발명은 다중 바이오마커를 이용한 치매 진단에 관한 것으로, 특히 동일한 질병인 치매에 대하여 베타 아밀로이드나 타우 등 다양한 바이오마커를 동시에 측정하여 치매를 진단하는 방법에 관한 것이다. 본 발명은 혈액, 뇌척수액 또는 기타 생체 샘플에서 다수의 바이오마커를 측정하여 치매의 존재를 보다 정확하게 진단할 수 있는 방법에 관련된다.
Resumen de: WO2020172645A1
Provided is a system for detecting a user of a bathroom. The system comprises at least one sensor coupled to a bathroom use analysis device, where the sensor generates data that can be used to detect and/or identify the user. Also provided is a method of detecting a user of a bathroom. The method comprises analyzing data generated by the sensor in the above system to detect and/or identify the user.
Resumen de: CN122344254A
0001 本发明提供了一种识别ApoE的兔源单克隆抗体，属于生物工程和生物检测技术领域。该单克隆抗体记为HZK31，包括HZK31‑B0002、HZK31‑B0005、HZK31‑B0007、HZK31‑B0011。本发明制备的兔源单克隆抗体可以高效特异性地识别人源ApoE。相比于小鼠或大鼠，本发明的兔源单克隆抗体结构更简单，具有更高的亲和力，更易于人源化。
Resumen de: KR20260104904A
0001a 본 발명은 펩타이드 리간드 코팅 팁에 관한 것으로, 특히 광산화 증폭 면역 분석 기기에 사용되는 펩타이드 리간드를 안정적이고 효율적으로 코팅할 수 있는 팁을 제공하는 것이다.
Resumen de: KR20260104836A
0001a 본 발명은 2채널 고감도 면역분석 자동화 기기에 관한 것으로, 특히 광산화 증폭을 이용하여 소량의 혈액 샘플로 질병을 파악하되, 퇴행성 뇌질환과 심혈관 질환을 동시에 현장에서 진단할 수 있는 2채널 고감도 면역분석 자동화 기기에 관한 것이다.
Resumen de: KR20260105078A
본 발명은 다채널 멀티 카트리지 고감도 면역분석 시스템에 관한 것으로, 특히 광산화 증폭을 이용하여 소량의 혈액 샘플로 질병을 파악하되, 하나의 질병에 대하여 다중 바이오마커를 이용하여 정밀하고 정확하게 현장에서 진단할 수 있는 다채널 멀티 카트리지 고감도 면역분석 시스템에 관한 것이다.
Resumen de: WO2025120373A1
Methods of determining the potency of a human neonatal Fc receptor (FcRn) antagonist composition in inhibiting the binding of human IgG to FcRn using a competition binding assay are provided. Kits for carrying out said methods, and methods of manufacturing a FcRn antagonist composition comprising said methods of determining potency are also provided.
Resumen de: CN122326739A
本发明公开了血清标志物miR‑206在制备阿尔茨海默病诊断产品中的应用，本发明首次将血清标志物miR‑206用于阿尔茨海默病的有效诊断与辅助诊断中，并且具有极高的诊断性能。本发明为开发稳定、可靠的阿尔茨海默病即时检测试剂盒或自动化化学发光检测系统等体外诊断产品奠定了技术与数据基础，具有推动阿尔茨海默病早期筛查、辅助诊断从依赖复杂影像和脑脊液检查向便捷、无创的血液检测转变的重大临床应用前景。
Resumen de: CN122325600A
本发明提供一种用于诊断阿尔茨海默症的抗体及其制备方法。申请人通过研究发现了几组抗体对，利用双抗夹心法检测p‑Tau217，亲和力和灵敏度高，对阿尔茨海默症的诊断具有十分积极的意义。
Resumen de: CN122325602A
本发明涉及免疫学技术领域，具体公开了一种抗Tau单克隆抗体及其应用，其重链的三个CDR区的氨基酸序列分别具有如SEQ ID NO:1、2和3所示的氨基酸序列；且其轻链的三个CDR区的氨基酸序列分别具有如SEQ ID NO:4、5和6所示的氨基酸序列。本发明提供的抗Tau单克隆抗体能够结合Tau蛋白N端投射区域，特异性识别Tau蛋白N端Thr95/Thr101磷酸化修饰位点，能用于人脑样本中Tau蛋白及其病理相关组分的免疫印迹检测，能用于转基因动物和人脑组织样本中Tau病理结构的组织学检测以及Tau蛋白相关疾病中的病理分期的研究。
Resumen de: CN122330416A
0001 本发明属于生物技术领域，公开了血清淀粉样P物质（SAP）作为生物标志物在制备诊断或预测射血分数保留型心力衰竭合并心房颤动（HFpEF合并AF）的产品中的应用。本发明通过构建HFpEF合并AF动物模型发现，SAP在动物模型中表达水平显著升高；在临床患者血浆样本中验证发现，HFpEF合并AF患者血浆中的SAP水平较对照组显著升高。因此，本发明通过对血浆中SAP进行定量检测，可实现对HFpEF合并AF的预测或诊断。
Resumen de: CN122330436A
0001 本发明公开了一种外泌体检测方法，包括将生物样本与裂解液混合得到样本裂解液的步骤；所述裂解液与生物样本的体积比为1:1。使用本发明中的提取外泌体和直接裂解两种方法检测TSG101和PDCD6IP浓度，所得检测结果具有较高的一致性，即本方法在提高效率的同时还具有较高的准确性。
Resumen de: CN122341632A
The present invention provides material compositions and/or methods useful for the prevention and/or treatment of protein depletion (proteopenia), comprising material compositions that retain the natural function of peptides/proteins while limiting and/or preventing amyloid formation and/or aggregation of the peptides/proteins. Also provided are material compositions and formulations for enhancing peptide/protein solubility, stability, cycle time, receptor interaction, brain permeability, CSF half-life, promoting peptide/protein synthesis and purification.
Nº publicación: WO2026141950A1 02/07/2026
Solicitante:
KUK IL GRAPHENE CO LTD [KR]
HEO CHAE JEONG [KR]
\uAD6D\uC77C\uADF8\uB798\uD540 \uC8FC\uC2DD\uD68C\uC0AC
\uD5C8\uCC44\uC815
Resumen de: WO2026141950A1
The present application provides: a spectroscopic analysis substrate for diagnosing dementia, comprising a hydrophilized graphene layer; and a spectroscopic device comprising same. More specifically, the present application provides: a spectroscopic analysis substrate for diagnosing dementia, having improved accuracy due to increased binding force and selectivity for amyloid beta, the substrate comprising a hydrophilized graphene layer; and a spectroscopic device comprising the spectroscopic analysis substrate.
BOPI
Sede Electrónica
